A prospective trial evaluating topographical distribution of tau pathology and its effect on functional and structural changes in healthy controls and patients with Alzheimer disease and mild cognitive impairment (MCI) by using 18F-AV-1451 PET.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flortaucipir-F-18 (Primary) ; Florbenazine F18
Indications Alzheimer's disease; Mild cognitive impairment
Focus Diagnostic use

Most Recent Events

14 Jul 2016 New trial record
29 Jun 2016 Results published in the Neurology

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight